Answers are grounded in this paper and cite their sources.
Pancreato-biliary cancers, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, and gallbladder cancer, develop through complex interactions within the tumor microenvironment. These tumors exhibit a dense stroma, immune suppression, and metabolic alterations that support growth and resistance to therapy. Crosstalk between cancer cells and stromal elements such as cancer-associated fibroblasts, tumor-associated macrophages, and myeloid-derived suppressor cells promotes progression through the transforming growth factor-β, interleukin-6/STAT3 (signal transducer and activator of transcription 3), CXCL12 (C-X-C motif chemokine ligand 12)/CXCR4, and Hedgehog pathways. Mutations in KRAS (Kirsten rat sarcoma viral oncogene homolog), TP53, and SMAD4 enhance these processes by enabling epithelial–mesenchymal transition, immune escape, and abnormal angiogenesis. Advances in single-cell and spatial transcriptomics, proteogenomics, and metabolomics have revealed immune and stromal patterns that are correlated with clinical outcomes and treatment response. These discoveries demonstrate that the tumor microenvironment actively drives disease progression. Current therapeutic efforts aim to modify the stroma, improve the vascular structure, reduce hypoxia, and combine immune checkpoint inhibitors with targeted or metabolic treatments. Nanotechnology-based delivery systems and organoid coculture platforms support precision approaches that reflect the spatial and functional features of the tumor microenvironment. A clearer understanding of these interactions is essential for overcoming resistance and improving patient outcomes through combined and individualized treatment strategies.
No takes yet. Share an insight, caveat, or question.
R et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: